好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Can Neuro-Qol Inform Us of Symptomatic Burden and Functional Disability Experienced by Patients Living with Stiff Person Syndrome Spectrum Disorders?
Autoimmune Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
2-005

To evaluate the potential use of the Quality of Life in Neurological Disorders (Neuro-QoL) questionnaires for assessment of symptomatic burden and functional disability in stiff person syndrome spectrum disorders (SPSD).

SPSD are rare, disabling neurological disorders that profoundly impact patients’ social, emotional, and physical well-being. Common complaints outside of impaired mobility include anxiety, sleep disturbances, and fatigue. Despite improving quality of life being central to SPSD care, there remains an unmet need for standardized health-related quality of life measures.

Data were collected across 10 Neuro-QoL domains for a convenience sample of 19 patients. Demographics, clinical characteristics, and T25FW measures were also collected. Spearman correlation or one-sample t-tests (reference mean=50) were used to determine associations as appropriate.

Nineteen patients with median age 60 [IQR 55-65] participated (13 classic SPS, 5 SPS-plus, 1 PERM). Initial symptom onset was 12 [IQR 9, 20] years. Most patients were female (84%) and White (74%). SPSD patients scored lower in social participation (t=-4.0, p=0.001) and satisfaction (t=-3.7, p=0.002). They also showed mild upper extremity and moderate lower extremity (LE) functional impairments (t=-3.7, p=0.002; t=-5.1, p=0.000, respectively). There was a strong negative correlation between LE and T25FW (rho=-0.92, p=0.001 for unassisted T25FW and rho=-0.82, p=0.034 for T25FW with bilateral assistance). Participants also scored worse in stigma (t=2.5, p=0.02). No other statistically significant differences were observed.

Neuro-QoL questionnaires may provide clinicians with a valuable tool for assessing QoL in SPSD, supporting more patient-centered care. The Neuro-QoL limb function domains can be used to measure patients’ current capabilities across these areas, while other domains may be more suited for monitoring changes over time due to their use of a defined recall period. Given these complementary strengths, Neuro-QoL measures may also be useful in clinical trials to capture both functional status and QoL outcomes in a standardized, patient-reported format.
Authors/Disclosures
Hanyeh Afshar
PRESENTER
Ms. Afshar has nothing to disclose.
Herbert Chen Herbert Chen has nothing to disclose.
Jaida M. Appiah Miss Appiah has nothing to disclose.
Scott D. Newsome, DO, FAAN (Johns Hopkins Hospital) Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. The institution of Dr. Newsome has received research support from Kyverna Therapeutics. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.